αvβ5+ Tumor-Resident Treg Targeting for PDAC Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pancreatic ductal adenocarcinoma (PDAC) is resistant to immunotherapy due to a prevalent immunosuppressive microenvironment driven by regulatory T cells (Tregs), leading to poor prognosis and diminished response to immune checkpoint blockades, with existing Treg depletion methods causing systemic side effects.
Innovation Solution
Targeting tumor-resident Tregs expressing αvβ5 integrin using the iRGD peptide to achieve selective depletion, combined with immune checkpoint inhibitors, to enhance anti-tumor immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic Treg depletion methods are used to improve anti-tumor immunity, then the CD8/Treg ratio increases and tumor response improves, but autoimmune complications and serious side effects occur
Solution Approach 1:
The patent applies local quality by making Treg depletion tumor-specific rather than systemic. The iRGD peptide targets αvβ5 integrin which is overexpressed in PDAC tissue but not in normal tissues. This allows selective depletion of Tregs within the tumor microenvironment while preserving Tregs in other parts of the body, thereby improving anti-tumor immunity without causing autoimmune complications.
Solution Approach 2:
The iRGD peptide serves as an intermediary that mediates selective Treg depletion. It binds to αvβ5 integrin on Tregs within the tumor microenvironment and facilitates their depletion through immune checkpoint inhibitors, acting as a targeted delivery mechanism that spares systemic Tregs and prevents autoimmune side effects.
2Productivity
If conventional Treg depletion methods are used to enhance anti-tumor immunity, then tumor response to immunotherapy improves, but the tumor immune microenvironment is adversely altered
Solution Approach 1:
The invention applies local quality by confining Treg depletion to the tumor microenvironment through targeting αvβ5 integrin with iRGD peptide. This localized approach enhances tumor response by improving the CD8/Treg ratio at the tumor site while maintaining the stability and composition of the broader tumor immune microenvironment, avoiding the adverse alterations caused by systemic depletion.
3Quantity of substance
If pan-Treg targeting approaches are used to deplete Tregs, then the CD8/Treg ratio increases, but off-target effects and systemic side effects occur
Solution Approach 1:
The patent implements local quality by using iRGD peptide to target αvβ5 integrin specifically in PDAC tissue where this integrin is overexpressed. This creates a spatially selective depletion effect that increases the CD8/Treg ratio at the tumor site while avoiding off-target effects in other tissues and organs, thereby eliminating systemic side effects.
Solution Approach 2:
The invention utilizes parameter changes by exploiting the differential expression levels of αvβ5 integrin. The integrin is highly expressed in PDAC tissue but minimally expressed in normal tissues. By targeting this parameter (integrin expression level), the method achieves selective Treg depletion in the tumor microenvironment without affecting Tregs in healthy tissues, thus avoiding off-target effects.
Data Source
AI summary
Pancreatic ductal adenocarcinoma (PDAC) has abundant immunosuppressive regulatory T cells (Tregs) which contribute to a tumor microenvironment that is resistant to immunotherapy. Tregs in the PDAC tissue, but not those in the spleen, express the αvβ5 integrin in addition to neuropilin-1 (NRP-1), which makes them susceptible to the iRGD tumor-penetrating peptide that targets αv integrin- and NRP1-positive cells. As a result, long-term treatment of PDAC mice with iRGD leads to a tumor-specific decrease of Tregs and improved efficacy of an immune checkpoint blockade. αvβ5 integrin+ Tregs are induced from both naïve CD4+ T cells and natural Tregs upon T cell receptor stimulation, and represent a highly immunosuppressive subpopulation of CCR8+ Tregs. This study identifies αvβ5 integrin as a marker for activated tumor-resident Tregs that can be expanded to achieve tumor-specific Treg depletion to improve anti-tumor immunity for PDAC management.